193 related articles for article (PubMed ID: 29282364)
1. Mir-pharmacogenetics of Vincristine and peripheral neurotoxicity in childhood B-cell acute lymphoblastic leukemia.
Gutierrez-Camino Á; Umerez M; Martin-Guerrero I; García de Andoin N; Santos B; Sastre A; Echebarria-Barona A; Astigarraga I; Navajas A; Garcia-Orad A
Pharmacogenomics J; 2018 Dec; 18(6):704-712. PubMed ID: 29282364
[TBL] [Abstract][Full Text] [Related]
2. Vincristine pharmacokinetics pathway and neurotoxicity during early phases of treatment in pediatric acute lymphoblastic leukemia.
Lopez-Lopez E; Gutierrez-Camino A; Astigarraga I; Navajas A; Echebarria-Barona A; Garcia-Miguel P; Garcia de Andoin N; Lobo C; Guerra-Merino I; Martin-Guerrero I; Garcia-Orad A
Pharmacogenomics; 2016 May; 17(7):731-41. PubMed ID: 27180762
[TBL] [Abstract][Full Text] [Related]
3. Involvement of miRNA polymorphism in mucositis development in childhood acute lymphoblastic leukemia treatment.
Gutierrez-Camino Á; Umerez M; Lopez-Lopez E; Santos-Zorrozua B; Martin-Guerrero I; de Andoin NG; Ana S; Navajas A; Astigarraga I; Garcia-Orad A
Pharmacogenomics; 2018 Dec; 19(18):1403-1412. PubMed ID: 30479191
[TBL] [Abstract][Full Text] [Related]
4. MiR-pharmacogenetics of methotrexate in childhood B-cell acute lymphoblastic leukemia.
Iparraguirre L; Gutierrez-Camino A; Umerez M; Martin-Guerrero I; Astigarraga I; Navajas A; Sastre A; Garcia de Andoin N; Garcia-Orad A
Pharmacogenet Genomics; 2016 Nov; 26(11):517-525. PubMed ID: 27649261
[TBL] [Abstract][Full Text] [Related]
5. Polymorphisms of the vincristine pathway and response to treatment in children with childhood acute lymphoblastic leukemia.
Ceppi F; Langlois-Pelletier C; Gagné V; Rousseau J; Ciolino C; De Lorenzo S; Kevin KM; Cijov D; Sallan SE; Silverman LB; Neuberg D; Kutok JL; Sinnett D; Laverdière C; Krajinovic M
Pharmacogenomics; 2014 Jun; 15(8):1105-16. PubMed ID: 25084203
[TBL] [Abstract][Full Text] [Related]
6. Variants in vincristine pharmacodynamic genes involved in neurotoxicity at induction phase in the therapy of pediatric acute lymphoblastic leukemia.
Martin-Guerrero I; Gutierrez-Camino A; Echebarria-Barona A; Astigarraga I; Garcia de Andoin N; Navajas A; Garcia-Orad A
Pharmacogenomics J; 2019 Dec; 19(6):564-569. PubMed ID: 30723315
[TBL] [Abstract][Full Text] [Related]
7. Severe life threatening neurotoxicity in a child with acute lymphoblastic leukemia receiving posaconazole and vincristine.
Jain S; Kapoor G
Pediatr Blood Cancer; 2010 May; 54(5):783. PubMed ID: 20205256
[No Abstract] [Full Text] [Related]
8. Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia.
Egbelakin A; Ferguson MJ; MacGill EA; Lehmann AS; Topletz AR; Quinney SK; Li L; McCammack KC; Hall SD; Renbarger JL
Pediatr Blood Cancer; 2011 Mar; 56(3):361-7. PubMed ID: 21225912
[TBL] [Abstract][Full Text] [Related]
9. Genetic factors influencing the development of vincristine-induced neurotoxicity.
Pozzi E; Fumagalli G; Chiorazzi A; Canta A; Cavaletti G
Expert Opin Drug Metab Toxicol; 2021 Feb; 17(2):215-226. PubMed ID: 33283553
[No Abstract] [Full Text] [Related]
10. Vincristine pharmacodynamics and pharmacogenetics in children with cancer: a limited-sampling, population modelling approach.
Moore AS; Norris R; Price G; Nguyen T; Ni M; George R; van Breda K; Duley J; Charles B; Pinkerton R
J Paediatr Child Health; 2011 Dec; 47(12):875-82. PubMed ID: 21658147
[TBL] [Abstract][Full Text] [Related]
11. Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia.
Diouf B; Crews KR; Lew G; Pei D; Cheng C; Bao J; Zheng JJ; Yang W; Fan Y; Wheeler HE; Wing C; Delaney SM; Komatsu M; Paugh SW; McCorkle JR; Lu X; Winick NJ; Carroll WL; Loh ML; Hunger SP; Devidas M; Pui CH; Dolan ME; Relling MV; Evans WE
JAMA; 2015 Feb; 313(8):815-23. PubMed ID: 25710658
[TBL] [Abstract][Full Text] [Related]
12. Severe neurotoxicities in a case of Charcot-Marie-Tooth disease type 2 caused by vincristine for acute lymphoblastic leukemia.
Nishikawa T; Kawakami K; Kumamoto T; Tonooka S; Abe A; Hayasaka K; Okamoto Y; Kawano Y
J Pediatr Hematol Oncol; 2008 Jul; 30(7):519-21. PubMed ID: 18797198
[TBL] [Abstract][Full Text] [Related]
13. Genetic polymorphisms in candidate genes are not associated with increased vincristine-related peripheral neuropathy in Arab children treated for acute childhood leukemia: a single institution study.
Zgheib NK; Ghanem KM; Tamim H; Aridi C; Shahine R; Tarek N; Saab R; Abboud MR; El-Solh H; Muwakkit SA
Pharmacogenet Genomics; 2018 Aug; 28(8):189-195. PubMed ID: 30119132
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenetics and induction/consolidation therapy toxicities in acute lymphoblastic leukemia patients treated with AIEOP-BFM ALL 2000 protocol.
Franca R; Rebora P; Bertorello N; Fagioli F; Conter V; Biondi A; Colombini A; Micalizzi C; Zecca M; Parasole R; Petruzziello F; Basso G; Putti MC; Locatelli F; d'Adamo P; Valsecchi MG; Decorti G; Rabusin M
Pharmacogenomics J; 2017 Jan; 17(1):4-10. PubMed ID: 26644204
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and pharmacodynamics of vincristine sulfate liposome injection (VSLI) in adults with acute lymphoblastic leukemia.
Silverman JA; Reynolds L; Deitcher SR
J Clin Pharmacol; 2013 Nov; 53(11):1139-45. PubMed ID: 23907766
[TBL] [Abstract][Full Text] [Related]
16. Decrease in motor performance in children with cancer is independent of the cumulative dose of vincristine.
Hartman A; van den Bos C; Stijnen T; Pieters R
Cancer; 2006 Mar; 106(6):1395-401. PubMed ID: 16453332
[TBL] [Abstract][Full Text] [Related]
17. Pharmacoepigenetics in childhood acute lymphoblastic leukemia: involvement of miRNA polymorphisms in hepatotoxicity.
Gutierrez-Camino A; Umerez M; Santos B; Martin-Guerrero I; García de Andoin N; Sastre A; Navajas A; Astigarraga I; Garcia-Orad A
Epigenomics; 2018 Apr; 10(4):409-417. PubMed ID: 29569486
[TBL] [Abstract][Full Text] [Related]
18. Vincristine-induced neuropathy as the initial presentation of charcot-marie-tooth disease in acute lymphoblastic leukemia: a Pediatric Oncology Group study.
Chauvenet AR; Shashi V; Selsky C; Morgan E; Kurtzberg J; Bell B;
J Pediatr Hematol Oncol; 2003 Apr; 25(4):316-20. PubMed ID: 12679647
[TBL] [Abstract][Full Text] [Related]
19. Vincristine-induced paralytic ileus during induction therapy of treatment protocols for acute lymphoblastic leukemia in adult patients.
Yasu T; Ohno N; Kawamata T; Kurokawa Y
Int J Clin Pharmacol Ther; 2016 Jun; 54(6):471-3. PubMed ID: 27087157
[TBL] [Abstract][Full Text] [Related]
20. Polymorphisms of ABCC5 and NOS3 genes influence doxorubicin cardiotoxicity in survivors of childhood acute lymphoblastic leukemia.
Krajinovic M; Elbared J; Drouin S; Bertout L; Rezgui A; Ansari M; Raboisson MJ; Lipshultz SE; Silverman LB; Sallan SE; Neuberg DS; Kutok JL; Laverdière C; Sinnett D; Andelfinger G
Pharmacogenomics J; 2016 Nov; 16(6):530-535. PubMed ID: 26345518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
